FEATURED EDITORIAL
The 2026 Inaugural Non-Opioid Pain Therapeutics Summit brought together a diverse group of scientists, clinicians, and drug hunters to discuss developing safe, effective pain medicines without the addictive properties associated with opioids.
- Targeting Underlying Biology: Novel Combination Therapies For Chronic Disease
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- Charting The Future Of Antimicrobial Resistance
- Annual Reflections And Predictions From The Editors' Roundtable
- The FXI Gamble: To Bleed Less... Or To Protect Less?
- Hibernating Squirrels May Hold Clues To Treating Heart Failure
- Engineering Therapeutics With A Structural Approach
FEATURED APPLICATION CONTENT
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
-
Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- Annual Reflections And Predictions From The Editors' Roundtable
- The Unlikely Weapon Against Fentanyl: Your Immune System
- 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026
FEATURED NEWS HEADLINES
- XtalPi Convenes Global Experts To Shape The Future Of Molecular Glue Drug Discovery: From Serendipity To Precision
- BioSelective Capital Investments Completes Acquisition Of BioDuro's Irvine, California Drug Product Development And Manufacturing Operations
- Zonsen PepLib Biotech Enters Global R&D Collaboration And License Agreement With Lilly
- New Boron Compounds Pave The Way For Easier Drug Development
- Exelixis Announces U.S. FDA Accepted The New Drug Application For Zanzalintinib In Combination With An Immune Checkpoint Inhibitor For Patients With Metastatic Colorectal Cancer
- Lupin And TB Alliance Join Forces To Advance Telacebec For The Treatment Of Tuberculosis And Other Mycobacterial Diseases
- TuHURA Biosciences Received FDA Orphan Drug Designation For IFx-2.0 For The Treatment Of Stage IIB To Stage IV Cutaneous Melanoma
- Onchilles Pharma Announces IND Clearance For N17350, Advancing The First Next-Generation Cytotoxic Therapeutic Leveraging The ELANE Pathway Into The Clinic
- Frontage Laboratories Expands Early Phase Clinical Capabilities To Support Global Drug Development
- VoxCell Appoints Chief Commercial Officer As Demand Grows For Predictive, Human-Relevant, Non-Clinical Testing Approaches
ARCHIVED NEWSLETTER
- 02.03.26 -- CROs In Early Drug Discovery, Part 3: Budgets, Timelines, And Avoiding Pitfalls
- 01.27.26 -- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- 01.20.26 -- CROs In Early Drug Discovery, Part 1: Choosing The Right Partner
- 01.13.26 -- Reflections And Predictions From The Editors' Roundtable
- 01.06.26 -- The Unlikely Weapon Against Fentanyl: Your Immune System